EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Original Vitamin Patch Pioneer Introduces Comprehensive Dopamine Precursor Formula Backed by Clinical ResearchLas Vegas, NV, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden...
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for...
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all...
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements...
BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that...
Expansion positions WellSpan as a leading AI-enabled health system, accelerating safer, faster and more effective care for patientsNEW YORK, Dec....
Acquisition adds eye-tracking-based ADHD medication management tool to HarmonEyes' growing human performance platformBETHESDA, Md., Dec. 10, 2025 /PRNewswire/ -- HarmonEyes,...
Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now...
Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now...
Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now...
Technomed Medical Unveils New Double and Triple Hooked Neuromonitoring Probes to Aid in Nerve Preservation Surgeons performing complex procedures now...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to...
Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to...
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of...